. Author manuscript; available in PMC: 2021 Mar 9.

Published in final edited form as: J Scleroderma Relat Disord. 2020 May 22;6(1):11–20. doi: 10.1177/2397198320915042

Table 2.

Mortality outcomes in recent SSc RCTs with >2 years of follow-up

Study Name	Intervention	ILD Presence	One-year mortality % (N)	Long-term mortality % (N)
SLS I²²	Oral CYC for vs. Placebo for 12 months	100%	CYC: 1% (2/79)Placebo: 5% (4/79)	CYC: 48% (38/79)
			Placebo: 5% (4/79)	Placebo: 35% (28/79)
			Placebo: 5% (4/79)	Median follow-up: 8 years
SLS II²⁶	Oral CYC for 12 months vs. MMF for 24 months	100%	CYC: 11% (8/73)	CYC: 22% (16/73)
			MMF: 3% (2/69)	MMF: 20% (14/69)
			MMF: 3% (2/69)	Median follow up: 3.6 years
SCOT²⁸	HSCT vs. IV CYC for 12 months	97%	HSCT:	HSCT: 17% (6/36)
SCOT²⁸	HSCT vs. IV CYC for 12 months	97%	CYC:	CYC: 28% (11/39) At 4.5 years
ASTIS²⁹	HSCT vs. IV CYC	87%	HSCT: 14% (11/79)	HSCT: 24% (19/79)
			CYC: 9% (7/77)	CYC: 30% (23/77)
			CYC: 9% (7/77)	Median follow up of 5.8 years

Abbreviations: CYC = cyclophosphamide; MMF = mycophenolate; HSCT = hematopoetic stem cell transplantation; IV = intravenous